NCT01126099

Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Seattle Institute for Biomedical and Clinical Research · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

A study of outpatient participants with Alzheimer's disease or a related dementia who have difficult behaviors that are upsetting for them or their caregivers. Prazosin is a medication that is commonly used to treat people with high blood pressure. Research with prazosin has shown that it may be effective in treating behavioral problems by reducing excess adrenalin effects in the brain.

Detailed description

This is a 24 week study with 14 visits to the research clinic. Approximately 6 of these visits may be done by phone. Additional phone checks are scheduled at the beginning of each 12 week part of the study. Participants will have a 50:50 chance of being on prazosin or placebo in the first 12 weeks of the study. For the second 12 weeks, all participants will take prazosin. Study visits include a physical and neurological exam; memory testing; interviews with the caregiver about behaviors; and vital signs.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	Prazosin	4 mg capsules twice daily for 12 weeks
DRUG	Placebo	Placebo capsules twice daily for 12 weeks

Timeline

• Start date: 2010-03-01
• Primary completion: 2014-03-01
• Completion: 2014-03-01
• First posted: 2010-05-19
• Last updated: 2015-05-21
• Results posted: 2015-05-21

Locations

1 site across 1 country: United States